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Answering the questions How can we monitor the health
of a population? How can we determine the effects of a
specific disease on that health? How can we compare the
health effects of many diseases, to determine which should
be addressed? requires rigorous inquiry based on estab-
lished techniques in epidemiology, biostatistics, economics,
psychometrics, and decision analysis. In addition to their
scientific interest and significance to our patients and
practices, these questions are important to the conduct
and goals of our research efforts, and to the public health.
The Burden of Skin Disease focus issue of the Journal is
devoted to studies that address these important issues. The
editors’ interest in this topic reflects a growing international
trend driven by a powerful confluence of political and
academic initiatives, including those of the World Bank and
the World Health Organization (Murray and Lopez, 1997)
and the US Institute of Medicine and the National Institutes
of Health (Gross et al, 1999).
For the purpose of this issue, burden of disease was defined
as the effects of disease on the overall welfare of a population,
which can be assessed from the viewpoints of the person, the
family, and society. Components of the burden of disease can
be either economic (related to costs incurred or income lost)
or non-economic (related to survival and well-being). Although
traditional measures of incidence and mortality are im-
portant, they provide an incomplete picture of the impact of
disease on affected patients, their families, and society.
Measuring such complex aspects of health is challenging,
and schemes and tools have been developed to measure
each of the components of the burden of disease. As with all
measurement tools, these instruments must at a minimum be
reliable (i.e., have a high signal-to-noise ratio) and valid (i.e.,
measure what they are intended to measure) (Chren, 2000).
In addition, we face unique challenges in attempting to
describe and measure the burden of skin disease. First, the
term ‘‘skin disease’’ is ambiguous, both with respect to the
term ‘‘skin’’ and the term ‘‘disease.’’ Biological conditions
often involve multiple organ systems, and there may be no
consensus on whether they primarily or predominantly
concern the skin.
A second challenge is that many skin diseases are chronic,
and their burden is experienced more in living with the disease,
than in dying from it. Thus, as with all chronic diseases,
accurate measures of well-being are especially important for
comprehensive assessments of burden of skin diseases.
These measures—of impairment, disability, and handicap—
can be difficult to develop, administer, and interpret, compared
with more straightforward measures of incidence andmortality.
A third challenge relates to the complex relationship
among impairment, disability, and handicap. For many—if
not most—clinical conditions (Nease et al, 1995; Nichol et al,
1996), the severity of the impairment, or biological proper-
ties of the disease, does not correlate in a predictable, linear
fashion with the disability of the patient. Likewise, a degree
of disability does not always handicap patients in the same
way. The complexity of this relationship, although true for
most diseases, is perhaps most pronounced for skin
diseases, which, because they can affect appearance and
self-esteem, may handicap more than they impair or
physically disable. A comprehensive assessment of handi-
cap requires input from patients themselves, for clinicians
are not able to predict accurately the quality-of-life effects
of their patients’ conditions (Parkerson et al, 1992).
It seems likely that national and global efforts to monitor
and compare overall health and the burden of individual
diseases will increase. As represented in the papers in this
focus issue of the Journal, we in dermatology must
articulate important and unique features about the burden
of skin diseases, and promote rigorous scientific ap-
proaches to measuring this burden. At the centerpiece of
our efforts should be our conviction that a comprehensive
assessment of the burden of skin disease requires not only
conventional measurements of incidence and mortality but
also accurate assessments of other dimensions of health,
including patients’ reports of disability and handicap.
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